Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Avidity Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$127M
Portfolio companies 24
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.04
Exits 6
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Health Diagnostics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Avidity Partners:
Typical Co-investors
Avidity Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Avidity Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Axxon Capital Boston, Massachusetts, United States
Bright Technologies Fund Lugano, Switzerland, Ticino
Capstar Partners Austin, Texas, United States
Climate-KIC Accelerator London Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Faad Network Delhi, India, New Delhi
Fluid Capital Group -
FMC Ventures Pennsylvania, Philadelphia, United States
Heller Financial Chicago, Illinois, United States
Instillo Germany, Saarland, Überherrn
Johnson Family Trust -
Level 5 Capital Partners Atlanta, Georgia, United States
Medina Heights Capital Partners New York, New York, United States
Prisma Energy International Houston, Texas, United States
Rooks Nest Ventures England, London, United Kingdom
Rosalind Advisors -
Seneca Ventures Seattle, United States, Washington
Srikrung Wattana Group -
Steigen -
Yueyou Touzi China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Dianthus Therapeutics

Biopharma
Biotechnology
Health Care
$100M19 Apr 2022 Waltham, Massachusetts, United States

Endeavor BioMedicines

Biotechnology
$101M07 Feb 2022 California, United States

AN2 Therapeutics

Biotechnology
Health Care
Pharmaceutical
$80M07 Jan 2022 California, United States

Hyperfine

Health Care
Medical Device
$126M23 Dec 2021 Guilford, Connecticut, United States

Innovaccer

Analytics
Big Data
Health Care
Information Services
$150M15 Dec 2021 San Francisco, California, United States

connectRN

Health Care
Hospital
Marketplace
Medical
Mobile Apps
Nursing and Residential Care
$76M08 Dec 2021 Boston, Massachusetts, United States

Sirona Medical

Artificial Intelligence
Health Care
Health Diagnostics
Software
$40M09 Nov 2021 San Francisco, California, United States

Alpine Immune Sciences

Biotechnology
Health Care
Medical
$91M15 Sep 2021 Seattle, Washington, United States

GentiBio

Biotechnology
Life Science
$157M11 Aug 2021 Seattle, Washington, United States
News
GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Avidity Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: